A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

April 27, 2021

Study Completion Date

August 9, 2021

Conditions
Chronic BronchitisChronic Obstructive Pulmonary Disease
Interventions
DRUG

ION-827359

ION-827359 administered by oral inhalation

DRUG

Placebo

Placebo administered by oral inhalation

DRUG

ION-827359

ION-827359 administered by oral inhalation

Trial Locations (15)

2900

Selye Janos Korhaz, Rendelointezet, Komárom

6772

Csongrad Megyei Mellkasi Betegsegek Szakkorhaza, Deszk

10969

Pneumologisches Studienzentrum Markgrafenstrasse, Berlin

12203

MECS Research GmbH, Berlin

20354

Hamburger Institut far Therapieforschung GmbH, Hamburg

22927

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf

23552

KLB Gesundheitsforschung Lubeck GmbH, Lübeck

27801

Plicni ambulance Kralupy, Kralupy nad Vltavou

33701

Plicni Ambulance Rokycany, s.r.o., Rokycany

37701

MediTrial s.r.o., Jindřichův Hradec

40747

PNEUMOLOGIE VARNSDORF s.r.o., Varnsdorf

48231

ZMS-Zentrum fur medizinische Studien GmbH, Warendorf

55128

IKF Pneumologie Mainz Helix Medical Excellence Center Mainz, Mainz

410 02

CEFISPIRO s.r.o., Lovosice

Nw1 8HU

Queen Anne Street Medical Centre, Heart Lung Center, London

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY